Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,152.54 -29.33 (-2.48%)

Official Closing Price Updated: 7:00 PM EDT, Jul 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Warren Buffett Has Recommended 1 Investment for Decades -- but There's a Hidden Risk Many Investors Are Overlooking ↗

July 07, 2026

This key factor didn't exist when Buffett first gave the advice, but does that change its appeal?

Via The Motley Fool

Eli Lilly's Market Cap Balloons Again On This IPO's Setback ↗

July 07, 2026

Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug.

Via Investor's Business Daily

Topics Initial Public Offering

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? ↗

July 07, 2026

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. ↗

July 07, 2026

The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.

Via The Motley Fool

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗

July 06, 2026

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Via MarketBeat

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 06, 2026

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Via The Motley Fool

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗

July 06, 2026

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Via The Motley Fool

Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗

July 06, 2026

Lilly offers investors safety and growth.

Via The Motley Fool

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗

July 05, 2026

Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.

Via The Motley Fool

Topics ETFs Intellectual Property

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗

July 05, 2026

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

Via The Motley Fool

Topics ETFs

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗

July 05, 2026

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Via The Motley Fool

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗

July 04, 2026

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

Via The Motley Fool

Topics ETFs

State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗

July 04, 2026

Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up? ↗

July 04, 2026

Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.

Via The Motley Fool

Topics ETFs

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗

July 04, 2026

Compare fees, diversification, and risk between these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗

July 04, 2026

The stock is known to soar on good news.

Via The Motley Fool

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly? ↗

July 03, 2026

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Via The Motley Fool

Dr. Danielle Carrera’s Beyond Better, Thrive Debuts as Amazon #1 New Release and Top 5 Bestseller

July 03, 2026

Via Get News

Here's Why Viking Therapeutics Stock Surged Higher in June ↗

July 03, 2026

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Via The Motley Fool

SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗

July 02, 2026

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China ↗

July 01, 2026

Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.

Via Benzinga

$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today ↗

July 01, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity

July 01, 2026

From Biotech Insider

Via GlobeNewswire

Q1 Rundown: Phibro Animal Health (NASDAQ:PAHC) Vs Other Branded Pharmaceuticals Stocks

June 30, 2026

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Phibro Animal Hea...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest

June 30, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Illumina (ILMN) Stock Is Down Today

June 30, 2026

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 1.9% in the afternoon session after Swiss drugmaker Roche launched a next-generation ge...

Via StockStory

Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness ↗

June 30, 2026

FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.

Via Benzinga

3 Magnificent Dividend ETFs That Could Supercharge Your Passive Income ↗

June 30, 2026

All three ETFs complement each other well in a portfolio.

Via The Motley Fool

Topics ETFs Stocks

Ranking Wall Street's Trillion-Dollar Stocks From Most to Least Attractive, Based on Future Cash Flow ↗

June 30, 2026

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are a handful of bargains and pretenders.

Via The Motley Fool

Topics Artificial Intelligence Stocks

5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX ↗

June 30, 2026

SpaceX recently completed a record IPO.

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.